SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SKYEY - SkyePharma PLC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dr. John M. de Castro who wrote (21)4/21/1999 5:36:00 PM
From: Dr. John M. de Castro  Read Replies (1) of 56
 
SKYEY filed and ANDA for Pemoline, a drug for ADD (attention deficit disorder). This was revealed for the first time in SKYEY's preliminary announcement of 1998 results. Pemoline is currently marketed by Abbott. Does anyone have information on Pemoline's sales and market share. The ADD market is huge and growing. But, to evaluate SKYEY's prospects we need some understanding of the market size for Pemoline.

Another interesting tid bit from the conference call was that the convertible debentures are 80% converted to SkyePharma shares. This would tend to indicate that my worry that this would stimulate short selling like a floorless convertible was not justified. The Brits appear to use this financing mechanism in a more responsible manner than US investors.

John de C
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News